Patent(s) and the Corresponding Patented Drug(s) |
Top |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US9493447 |
Title |
Optically active PDE10 inhibitor |
Abstract |
The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. |
Applicant(s) |
Omeros Corporation |
Representative Drug(s) |
D0EN2M |
Drug Info
|
IC50 > 10000nM |
[1] |
Patent ID |
US9173884 |
Title |
Inhibitors of phosphodiesterase 11 (PDE11) |
Abstract |
The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject. |
Applicant(s) |
Trustees of Boston College |
Representative Drug(s) |
D0Z7YQ |
Drug Info
|
IC50 > 100000nM |
Click to Show More |
[2] |
2
|
D0SH7F
|
Drug Info
|
IC50 > 100000nM
|
[2] |
Patent ID |
US9173884 |
Title |
Inhibitors of phosphodiesterase 11 (PDE11) |
Abstract |
The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject. |
Applicant(s) |
Trustees of Boston College |
Representative Drug(s) |
D0Z7YQ |
Drug Info
|
IC50 > 100000nM |
Click to Show More |
[2] |
2
|
D0SH7F
|
Drug Info
|
IC50 > 100000nM
|
[2] |
Patent ID |
US9173884 |
Title |
Inhibitors of phosphodiesterase 11 (PDE11) |
Abstract |
The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject. |
Applicant(s) |
Trustees of Boston College |
Representative Drug(s) |
D0Z7YQ |
Drug Info
|
IC50 > 100000nM |
Click to Show More |
[2] |
2
|
D0SH7F
|
Drug Info
|
IC50 > 100000nM
|
[2] |
Patent ID |
US9173884 |
Title |
Inhibitors of phosphodiesterase 11 (PDE11) |
Abstract |
The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject. |
Applicant(s) |
Trustees of Boston College |
Representative Drug(s) |
D0Z7YQ |
Drug Info
|
IC50 > 100000nM |
Click to Show More |
[2] |
2
|
D0SH7F
|
Drug Info
|
IC50 > 100000nM
|
[2] |
Patent ID |
US8846654 |
Title |
Therapeutic applications in the cardiovascular field of quinazolinedione derivatives |
Abstract |
A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. |
Applicant(s) |
Sanofi |
Representative Drug(s) |
D05SRL |
Drug Info
|
IC50 = 15 nM |
Click to Show More |
[3] |
2
|
D0EF6R
|
Drug Info
|
IC50 = 140 nM
|
[3] |
3
|
D0A5JS
|
Drug Info
|
IC50 = 390 nM
|
[3] |
Patent ID |
US8846654 |
Title |
Therapeutic applications in the cardiovascular field of quinazolinedione derivatives |
Abstract |
A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. |
Applicant(s) |
Sanofi |
Representative Drug(s) |
D05SRL |
Drug Info
|
IC50 = 15 nM |
Click to Show More |
[3] |
2
|
D0EF6R
|
Drug Info
|
IC50 = 140 nM
|
[3] |
3
|
D0A5JS
|
Drug Info
|
IC50 = 390 nM
|
[3] |
Patent ID |
US8846654 |
Title |
Therapeutic applications in the cardiovascular field of quinazolinedione derivatives |
Abstract |
A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. |
Applicant(s) |
Sanofi |
Representative Drug(s) |
D05SRL |
Drug Info
|
IC50 = 15 nM |
Click to Show More |
[3] |
2
|
D0EF6R
|
Drug Info
|
IC50 = 140 nM
|
[3] |
3
|
D0A5JS
|
Drug Info
|
IC50 = 390 nM
|
[3] |